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outcomes and greater indirect costs. The distribution of BMI is similar to the 5 E.U. 
Finding suggest the need for additional weight-loss options.
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Objectives: MCD, an ultra-orphan lymphoproliferative disorder with heteroge-
neous symptomology, including fatigue, malaise, sweats, and nodal/extranodal 
masses, is driven by dysregulated interleukin-6 signaling. Siltuximab, an anti-
interleukin-6 antibody, is approved in the US and EU for treatment of human immu-
nodeficiency virus (HIV) - and human herpes virus-8 (HHV-8) -negative adult MCD 
patients. This study aimed to fill an unmet need for a validated PRO tool to quantify 
MCD symptoms and responses to therapy. MethOds: Using FDA guidance, an MCD 
symptom scale (MCD-SS) was developed by collecting and evaluating symptoms 
in 12 patients from 2 US centers, with further validation using additional patients 
from 1 US center. Item performance, scale structure and scoring, reliability, validity, 
responsiveness, and clinically meaningful change were evaluated in a randomized, 
placebo-controlled, double-blind study of siltuximab (N= 79) in HIV-, HHV-8-negative 
MCD patients (Wong Blood 2013:122 (21)). Results: Patient-reported MCD symp-
toms were: cough, dizziness, drowsiness, dry mouth, fever, headaches, hot flashes, 
itching, skin lesions, loss of appetite, nausea, numbness/tingling, pain, rash, short-
ness of breath, sweating, swollen lymph nodes, swelling/edema, tiredness/fatigue, 
vomiting, weakness, weight gain, and weight loss. Following exploratory factor 
analysis, 3 domains were created: fatigue, rash/itching, and sweats (total score also 
calculated). The final MCD-SS comprised 16 questions with 6 response options: “did 
not experience,” “very mild,” “mild,” “moderate,” “severe,” and “very severe” (score, 
0-5). Subjects reported a mean (SD) and median (range) of 9.2 (3.76) and 9.5 (1-16) 
symptoms, respectively. Test-retest reliability was acceptable (r> 0.70) for fatigue, 
sweats, and the total score but lower for rash/itching (r= 0.65). Internal consistency 
exceeded 0.70 for all. Lower ECOG scores were associated with lower MCD-SS scores. 
MCD-SS total scores were moderately correlated (r= 0.48) with baseline clinician-
reported signs and symptoms. cOnclusiOns: This is the first known attempt to 
develop a PRO instrument for MCD. These data support further use of the MCD-SS 
in the target population.
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Objectives: Systemic sclerosis (SSc) is a rare, multisystem chronic disease char-
acterised by fibrotic changes affecting all or some bodily organs. SSc is associated 
with high morbidity and a significant effect on patients’ health-related quality 
of life. Qualitative insights can provide rich context to the patients’ experience 
of a disease. Conceptual models based on qualitative data are a valuable way to 
“explain, with graphically or narrative form, the main things to be studied - the key 
factors, concepts and variables – and the presumed relationships between them”. 
Despite the existence of SSc-specific measures, no conceptual model of SSc exists. 
This research aimed to develop a qualitatively-derived, patient-centred, conceptual 
model of SSc. MethOds: To identify patient-reported SSc symptoms and impacts, 
we reviewed qualitative literature (published since 2000 to limit the search) in 
which experiences of living/coping with SSc are described. We also reviewed social 
media blogs/forums to identify additional concepts and provide supporting quotes. 
Concepts were identified by independent researchers who collaboratively developed 
the model. Results: Twelve qualitative studies and 150 social media posts were 
reviewed. The review identified 56 symptom concepts, which were categorised into 
13 domains (peripheral, cognitive, pain, neurological, cardiorespiratory, ophthalmo-
logical, gastrointestinal, fatigue, nasopharyngeal, weight, oesophageal, dizziness, 
nausea) and 48 impact concepts, which were categorised into 8 domains (daily living, 
diet, social, clothing, work, physical and psychological functioning). Of note, nausea 
and dizziness were identified only through the social media review. cOnclusiOns: 
A conceptual model for SSc was developed based on qualitative insights. The model 
depicts the diverse range of symptoms and impacts experienced by patients. By 
incorporating a social media review, relevant symptoms, which would not have 
otherwise been identified, were found and included in the model. This research is 
an important first step in identifying the most relevant and conceptually compre-
hensive clinical outcomes assessments for clinical research/practice.
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Objectives: The objectives of this study were to investigate the prevalence of 
Neuropathic Pain (NP) and newly occurred (de novo) NP postoperatively. This study 
also aimed to identify the disease burden (pain severity and quality of life (QoL)) 
of NP. MethOds: This study was a nationwide, multi-centered, prospective, and 
1Pharmerit International, Cambridge, MA, USA, 2Pharmerit International, Bethesda, MD, USA, 
3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 4Novartis Pharma AG, Basel, 
Switzerland
Objectives: Adherence to iron chelation therapy (ICT) is essential for patients with 
transfusion-dependent anemia (TDA) (e. g., sickle cell disease [SCD] and thalas-
semia) to increase survival and minimize disease-related sequellae. Adherence has 
been noted as especially problematic for children and adolescents. In order to meas-
ure compliance and treatment satisfaction in young children, the Satisfaction with 
Iron Chelation Therapy (SICT) instrument (initially developed for use by adults and 
adolescents) was modified to be an observer-reported outcome (ObsRO) measure to 
be administered electronically to caregivers. In addition, three other ObsROs were 
developed measuring compliance, palatability, and gastrointestinal (GI) symptoms 
related to treatment benefit of a new ICT formulation. MethOds: Subjects included 
10 caregivers of children with TDA. Informed consent was obtained. Two sets of 
face-to-face cognitive interviews were conducted iteratively with modification to 
items and further debriefing of modifications. Interviews began with an open-ended 
question to elicit caregivers’ and their reports of their child’s experiences with 
ICT. Interviews were audio recorded and transcribed. Data were analyzed using 
ATLAS. ti software. Results: Three interviewers conducted 10 caregiver inter-
views in 6 US cities. Caregivers were 90% female aged 35-65 (mean= 48). Children 
of caregivers included those with SCD (80%) and thalassemia (20%) and were 60% 
female, aged 2-17 (mean= 9). Responses to the open-ended question confirmed 
several concepts in the modified SICT and the need for new items. The result-
ant questionnaires included the modified SICT (17 items), Compliance (2 items), 
Palatability (4 items), and GI Symptom Diary (6 items). Changes were made to each 
to ensure comprehension, relevance, lack of redundancy, and appropriate response 
options. cOnclusiOns: Evidence supports the content validity of the modified 
SICT, Compliance, Palatability, and GI Symptom Diary questionnaires. Use in clinical 
research awaits tests of validity, reliability, and responsiveness.
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Objectives: Pulmonary exacerbations (PEs) in patients with cystic fibrosis (CF) 
have been reported to impact health-related quality of life. This analysis exam-
ined the impact of PEs on EQ-5D measures in patients with CF using trial-based 
data. MethOds: In a 48-week randomized, placebo-controlled study of ivacaftor 
in patients ≥ 12 years with CF and a G551D-CFTRmutation, the EQ-5D questionnaire, 
including visual analog scale (EQ VAS), was administered at baseline, 15 days, 8 
weeks, and every 8 weeks thereafter. UK preference weights were employed to 
derive the EQ-5D index. PE was defined as a change in antibiotic therapy for ≥ 4 of 
12 signs or predefined symptoms. EQ-5D measures collected in the 8-week pre- and 
post- exacerbation periods were examined after pooling observations across study 
treatments and visits. Results: A total of 146 PEs were experienced by 72 (44.7% of 
total 161) patients, including 52 (35.6%) PEs that required hospitalization. Mean (±SD) 
duration was 30.0±22.2 days for PEs requiring hospitalization (n= 48) and 20.6±11.6 
days for those not requiring hospitalization (n= 89) (9 PEs had missing end dates). 
For PEs requiring hospitalization, mean (±SD) EQ-5D index/VAS scores within 1-8 
weeks before PE start were 0.91 (±0.13)/75.5 (±14.2), respectively. The lowest aver-
age EQ-5D index/VAS scores were reached within 1 week of PE start; mean scores 
within 1 week were 0.76±0.33 (p= 0.044 vs. 1-8 weeks prior to PE) /63.7±24.1 (p= 0.039). 
Corresponding values for PEs not requiring hospitalization were 0.89±0.16/73.4±16.1 
within 1-8 weeks before PE start, and 0.90±0.13 (p= 0.777) /68.4±17.4 (p= 0.124) within 
1 week of PE start. cOnclusiOns: In a clinical study of patients with CF (≥ 12 years 
of age and a G551D-CFTR mutation), the PEs were associated with lower EQ-5D and 
VAS scores, primarily among those requiring hospitalization. Reducing PEs requir-
ing hospitalization is likely to improve health-related quality of life among these 
patients.
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Objectives: This study investigated the effect of BMI on quality of life, pro-
ductivity, activity impairment, health care resource-utilisation, and associated 
costs. MethOds: Results were from the 2011-2012 Brazil National Health and 
Wellness Survey (N= 24,000), a nationally representative, online survey of respond-
ents aged≥ 18 years. Analysis focused on normal weight (BMI≥ 18.5 & < 25 kg/m2), 
overweight (BMI≥ 25 & < 30 kg/m2), obese class (OC) I (BMI≥ 30 & < 35 kg/m2), OC II 
(BMI≥ 35 & < 40 kg/m2), and OC III (BMI≥ 40 kg/m2) respondents. Outcomes included 
quality of life (SF-36v2), health utilities (SF-6D), productivity loss (Work Productivity 
and Activity Impairment questionnaire) and resource utilisation (type/number of 
visits) in the past six months. Direct and indirect costs were estimated from public 
sources. Generalised linear models predicted outcomes as a function of BMI cat-
egory, adjusting for covariates (e. g., age, gender, comorbidities). Results: Among 
22,871 respondents, 46.4% were normal weight, 34.9% were overweight, 12.9% were 
OC I, 3.7% were OC II, and 2.0% were OC III. Adjusting for covariates, mental, physi-
cal component summary (normal weight: 51.8; overweight: 51.4; OC I: 50.3; OC II: 
48.5; OC III: 46.0), and health utilities (normal weight: 0.73; overweight: 0.72; OC I: 
0.71; OC II: 0.70; OC III: 0.67) decreased as BMI increased (OCs vs. normal, p< 0.05). 
Amongst the employed (66.1%), impairment while working (normal weight: 15.5%; 
overweight: 15.6%; OC I: 16.9%; OC II: 18.2%; OC III: 22.4%, OCs vs. normal, p< 0.05) 
increased as BMI increased. Normal weight (vs. OCs, p≤ 0.05) had lower activity 
impairment, fewer provider visits, and lower indirect costs (normal weight: R$333; 
overweight: R$338; OC I: R$385; OC II: R$395; OC III: R$458). cOnclusiOns: Over 
50% of Brazilians are overweight or obese. Increase in BMI is associated with poorer 
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during eight individual cognitive interviews. cOnclusiOns: The mixed-methods 
approach provides valuable support in the development of a fit-for-purpose instru-
ment assessing impacts of cLBP. Upon testing this revised PAL-I in a second pilot 
quantitative study, the final measure will undergo formal validation including sen-
sitivity to change.
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Objectives: 1) To identify orphan medicines indicated for lymphoproliferative dis-
orders approved by the European Medicines Agency (EMA); (2) To identify medicines 
for which a PRO evaluation was performed; (3) To list those with a PRO labeling claim, 
and (4) To identify reasons for not granting a PRO claim. MethOds: The search 
was performed on the EMA website (06/21/2014). The products were browsed by 
type (i. e., orphan medicines). Products refused and withdrawn were excluded. The 
PROLabels database was searched for each product retrieved to identify any PRO 
claim in the label. Summary of Product characteristics (SMPc) and CHMP Assessment 
Reports (AR) were retrieved for each product and analyzed to find out about PRO 
evaluation reported in the AR and not reported in the label. Results: Thirteen 
orphan medicines indicated in lymphoproliferative disorders were identified, rep-
resenting three main indications: lymphomas (Hodgkin, systemic anaplastic large 
cell, T-cell lymphoblastic, mantle-cell), leukemias (chronic lymphocytic, hairy cell, 
acute lymphoblastic) and multiple myeloma. Only one product had a PRO claim: 
ofatumumab (resolution of constitutional symptoms). The label of another product 
(brentuximab vedotin) indicated “resolution of B symptoms.” However, there was 
no mention in the AR on how the symptoms were collected (patient or clinician). 
For one product (pomalidomide), a HRQL evaluation was mentioned in the AR, but 
not reported in the label. However, there was no information about this evaluation 
in the AR and the reader is left to wonder about the HRQL results and the reasons 
for not including them in the label. cOnclusiOns: The percentage of PRO claims 
in orphan medicines (7.7%) is inferior to the percentage of PRO claims in all EMA 
products (26%). This is remarkably low considering the profound effect of lym-
phoproliferative disorders on patients’ life. Efforts should be made to improve the 
reporting of PRO data in the CHMP Assessment Reports.
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Objectives: Phenylketonuria (PKU) is a rare genetic disorder impacting pheny-
lalanine (Phe) metabolism. Treatment involves a lifelong Phe restricted diet that 
is strict and socially demanding. Even when treated early and well, mild cogni-
tive abnormalities have been seen. PKU can affect quality of life in individuals 
and their families. The phenylketonuria–quality of life (PKU-QOL) questionnaires 
are the first PKU-specific QOL questionnaires ever developed. The study aimed to 
perform the psychometric validation of these questionnaires. MethOds: An obser-
vational study was conducted in France, Germany, Italy, The Netherlands, Spain, 
Turkey and the UK to finalize and validate PKU-QoL questionnaires in individuals 
with treated PKU aged 9–11, 12–17 and ≥ 18 years, and in parents of individuals < 18 
years. Questionnaires were assessed for reliability (internal consistency, test–retest), 
concurrent validity (using three generic questionnaires adapted to the respondent: 
PedsQOL, SF-36 for adults and CHQ-PF28) and clinical validity (using PKU severity 
and overall assessment of patient health status). Results: In total, 559 participants 
(306 individuals, ages 9–45 years; 253 parents, ages 24–66 years) were included in the 
analysis. Return rate and quality of completion of the questionnaires were good, 
indicating good acceptability. Scores were defined to assess all relevant aspects of 
experiences: PKU symptoms, impact of PKU, dietary protein restriction and sup-
plementation. Reliability and validity were satisfactory overall for the adolescent, 
adult and parent PKU-QoL questionnaires, and slightly weaker but acceptable for 
the child version. cOnclusiOns: The four PKU-QOL questionnaires are valid and 
reliable instruments for assessing the specific quality of life aspects that are affected 
in individuals with PKU of different age groups (children, adolescents and adults) 
and their parents, and are available in seven languages. They are very promising 
tools for focused evaluation of PKU impact on individuals and parents in different 
countries, and for monitoring the efficacy of therapeutic strategies.
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Objectives: Dengue infection is a major cause of disease in tropical areas with 
an estimated 50 million infections occurring each year and more than 2.5 billion 
people being at risk of infections. The main objective of this study was to investigate 
relation between white blood cells and platelets during recovery phase in dengue 
hemorrhagic fever. MethOds: A retrospective multi-center study was conducted 
on 1000 seropositive cases of dengue fever. Results: More prevalence has been 
observed in male 880 (88%) as compared to female 120 (12%). A rapid fall in white 
blood cells count (WBC) was observed in initial CBC reports at start of disease then 
observational study. It was conducted from September 2011 to December 2012 and 
included a total of 1,109 patients who were scheduled for lumbar spinal surgery 
from 44 spinal centers (both orthopaedic surgery and neurosurgeons). Patients were 
diagnosed of having NP if the Leeds Assessment of Neuropathic Symptoms and 
Signs (LANSS) pain scale criteria were ≥ 12 points. The patients were investigated 
to assess their pain severity using pain numeric rating scale (NRS) and quality 
of life using EuroQol (EQ)-5D at baseline, after 1 week and 3 months of the sur-
gery. Results: Among 1,109 patents, at baseline, NP was identified in 404 (36%) 
patients. After 1 week and 3 months of the surgery, NP was found in 8.6% and 
4.0% patients respectively. Among the 705 patients without NP preoperatively, the 
prevalence of de novo NP occurred in the 1 week and 3 months of post-surgery was 
3.1% and 2.3% respectively. At baseline, NP patients showed lower QoL compared 
with non-NP patients (0.49 vs 0.53 p< .001). However, NP patients improved more 
their QoL compared to non-NP patients after 3 months (0.86 vs 0.84 p=.029). Among 
the de novo NP patients at 3 months after surgery (n= 16), the pain severity was not 
improved after 1 week and 3 months of the surgery. cOnclusiOns: In Korea, NP 
patients were suffered from severe pain and lower QoL than non-NP patients. De 
novo NP caused severe pain which may not easily be handled. Those study findings 
highlight that timely diagnosis and management of NP are required in patients 
with lumbar spine surgery.
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Objectives: The Pain Assessment for Lower Back Symptoms (PAL-S) is a Patient 
Reported Outcome (PRO) instrument being developed to assess the key symptoms 
of chronic low back pain (cLBP). Qualitative development included both concept 
elicitation and cognitive interviews. As part of the ongoing development of the 
instrument, we further evaluated and refined the PAL-S using a mixed methods 
approach. MethOds: Adults self-reporting a clinical diagnosis of cLBP were 
recruited from an existing US-based commercial survey panel to participate in 
a pilot quantitative study. Qualifying participants completed a web-based survey 
consisting of the 14-item PAL-S and items assessing clinical, treatment, and demo-
graphic characteristics. Study data was analyzed to assess item- and scale-level 
performance of the PAL-S using Rasch Measurement Theory analyses. Following 
analysis and modification, two waves of cognitive interviews were conducted to 
evaluate respondent understanding of the revised PAL-S. Results: The dataset 
included 598 respondents (mean age: 55.5±12.6; 67.9% female; 88.0% white; and 
54.0% married) who had cLBP for mean of 15.2±11.5 years. The Rasch analyses item 
threshold maps showed only two items having ordered thresholds, suggesting that 
respondents experienced increased difficulty distinguishing between options at 
the lower levels of the 0-10 scale. Simulations collapsing the responses to a best-
fit 4-point response scale resulted in improved ordering of thresholds, suggesting 
a more optimal response option structure. Based on these findings, the numeric 
response scale of the PAL-S items was replaced with a 4-point verbal rating scale 
incorporating response choices such as not at all, slight, moderate, and severe. Findings 
from eight cognitive interviews confirmed patient comprehension and relevance 
of the revised instrument. cOnclusiOns: The mixed-methods approach proved 
valuable to the ongoing development of the PAL-S, as Rasch analyses identified 
a need for refinement of the response scale. The measurement properties of the 
revised PAL-S will be evaluated in additional web-based and clinic-based quantita-
tive studies.
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Objectives: The Pain Assessment for Lower Back-Impacts (PAL-I) is a patient-
reported outcome (PRO) instrument being developed to assess key impacts, e. 
g. walking, sitting, standing, etc. associated with chronic low back pain (cLBP). 
Following a mixed methods approach, the PAL-I development included qualitative 
work (both concept elicitation and cognitive interviews) and now a quantitative 
“pilot study” evaluation for further content validity. MethOds: Adults self-report-
ing a clinical diagnosis of cLBP were recruited from a US-based commercial survey 
panel. Qualifying participants completed a web-based survey consisting of the 
13-item PAL-I and items assessing clinical, treatment, and demographic character-
istics. Study data was analyzed to assess item- and scale-level performance of the 
PAL-I using Rasch Measurement Theory analyses. Following analysis and modifica-
tion, cognitive interviews were conducted to evaluate patient understanding of the 
revised PAL-I. Results: The 598 subjects in the pilot study reported having cLBP 
(mean of 6.1 on 11-point numerical rating scale, 0= no pain). Subjects experienced 
cLBP for 0.3 to 66 years (mean 15.2, SD 11.5), were 55.5 years old (SD 12.6), 67.9% 
female, 88.0% white and 54.0% married. The Rasch item threshold map showed 
only 2 items having an ordered threshold identifying problems with the response 
categories. Category probability curves indicated subjects had “difficulty” endorsing 
items specifically in relation to the extreme options. Based on these findings, four 
items were removed and the response options were modified for the remaining 
items (from 6-point scale 4-point: Not at all limited, Limited a little, Limited a lot, Did 
not do). Comprehension of the revised instrument was evaluated and confirmed 
